(DIA) DiaSorin S.p.A. - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: MI (Italy) | Market Cap: 3.217m EUR | Total Return: -26.8% in 12m
Avg Turnover: 23.4M
Qual. Beats: 0
Rev. Trend: 0.1%
Qual. Beats: -1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
DiaSorin S.p.A. is an Italian biotechnology company specializing in the research, development, and global distribution of immunodiagnostic and molecular diagnostic testing kits. Its primary product lines include the LIAISON instrument series and Simplexa molecular assays, which target clinical areas such as infectious diseases, oncology, and metabolic disorders.
The company operates within the In Vitro Diagnostics (IVD) sector, where business models typically rely on a razor-and-blade strategy. This involves placing proprietary laboratory instruments at client sites to generate recurring high-margin revenue through the continuous sale of specialized consumable reagents and test kits.
DiaSorin further diversified its technological capabilities by integrating the xMAP multiplexing platform, which allows for the simultaneous detection of multiple analytes in a single sample. Investors can find deeper insights into these technical segments by exploring the data on ValueRay.
- Expansion of immunodiagnostic test menu drives recurring specialty reagent revenue growth
- Integration of Luminex xMAP technology enhances molecular diagnostics market share
- Post-pandemic normalization of respiratory testing volumes impacts year-over-year revenue comparisons
- Strategic shift toward higher-margin specialty testing offsets legacy diagnostic pricing pressure
- Regulatory approval timelines for Liaison Plex assays dictate North American expansion pace
| Net Income: 195.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.29 > 1.0 |
| NWC/Revenue: 16.90% < 20% (prev 46.72%; Δ -29.82% < -1%) |
| CFO/TA 0.12 > 3% & CFO 342.8m > Net Income 195.4m |
| Net Debt (-103.8m) to EBITDA (409.5m): -0.25 < 3 |
| Current Ratio: 1.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.9m) vs 12m ago -0.92% < -2% |
| Gross Margin: 65.86% > 18% (prev 0.62%; Δ 6.52k% > 0.5%) |
| Asset Turnover: 39.75% > 50% (prev 44.16%; Δ -4.41% > 0%) |
| Interest Coverage Ratio: 11.49 > 6 (EBITDA TTM 409.5m / Interest Expense TTM 24.5m) |
| A: 0.07 (Total Current Assets 759.6m - Total Current Liabilities 555.5m) / Total Assets 2.87b |
| B: 0.03 (Retained Earnings 99.4m / Total Assets 2.87b) |
| C: 0.09 (EBIT TTM 281.2m / Avg Total Assets 3.04b) |
| D: 0.07 (Book Value of Equity 99.4m / Total Liabilities 1.34b) |
| Altman-Z'' = 1.28 = BB |
| DSRI: 1.07 (Receivables 209.0m/228.7m, Revenue 1.21b/1.42b) |
| GMI: 0.94 (GM 65.86% / 62.15%) |
| AQI: 1.05 (AQ_t 0.65 / AQ_t-1 0.61) |
| SGI: 0.85 (Revenue 1.21b / 1.42b) |
| TATA: -0.05 (NI 195.4m - CFO 342.8m) / TA 2.87b) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at EUR 65.58 with a total of 158,114 shares traded.
Over the past week, the price has changed by -5.91%,
over one month by +11.69%,
over three months by -4.31% and
over the past year by -26.76%.
DiaSorin S.p.A. has no consensus analysts rating.
P/E Trailing = 24.4697
P/E Forward = 21.0526
P/S = 2.7516
P/B = 2.1488
P/EG = 1.5472
Revenue TTM = 1.21b EUR
EBIT TTM = 281.2m EUR
EBITDA TTM = 409.5m EUR
Long Term Debt = 472.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 227.9m EUR (from shortLongTermDebt, last quarter)
Debt = 69.2m EUR (Leases only: 69.2m)
Net Debt = -103.8m EUR (calculated: Debt 69.2m - CCE 173.1m)
Enterprise Value = 3.11b EUR (3.22b + Debt 69.2m - CCE 173.1m)
Interest Coverage Ratio = 11.49 (Ebit TTM 281.2m / Interest Expense TTM 24.5m)
EV/FCF = 15.18x (Enterprise Value 3.11b / FCF TTM 205.1m)
FCF Yield = 6.59% (FCF TTM 205.1m / Enterprise Value 3.11b)
FCF Margin = 16.97% (FCF TTM 205.1m / Revenue TTM 1.21b)
Net Margin = 16.17% (Net Income TTM 195.4m / Revenue TTM 1.21b)
Gross Margin = 65.86% ((Revenue TTM 1.21b - Cost of Revenue TTM 412.6m) / Revenue TTM)
Gross Margin QoQ = 65.93% (prev 65.18%)
Tobins Q-Ratio = 1.09 (Enterprise Value 3.11b / Total Assets 2.87b)
Interest Expense / Debt = 35.35% (Interest Expense 24.5m / Debt 69.2m)
Taxrate = 26.76% (16.7m / 62.4m)
NOPAT = 206.0m (EBIT 281.2m * (1 - 26.76%))
Current Ratio = 1.37 (Total Current Assets 759.6m / Total Current Liabilities 555.5m)
Debt / Equity = 0.05 (Debt 69.2m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -0.25 (Net Debt -103.8m / EBITDA 409.5m)
Debt / FCF = -0.51 (Net Debt -103.8m / FCF TTM 205.1m)
Total Stockholder Equity = 1.61b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.43% (Net Income 195.4m / Total Assets 2.87b)
RoE = 12.11% (Net Income TTM 195.4m / Total Stockholder Equity 1.61b)
RoCE = 13.48% (EBIT 281.2m / Capital Employed (Equity 1.61b + L.T.Debt 472.1m))
RoIC = 8.91% (NOPAT 206.0m / Invested Capital 2.31b)
WACC = 7.26% (E(3.22b)/V(3.29b) * Re(6.86%) + D(69.2m)/V(3.29b) * Rd(35.35%) * (1-Tc(0.27)))
Discount Rate = 6.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -29.55 | Cagr: -0.27%
[DCF] Terminal Value 73.24% ; FCFF base≈218.7m ; Y1≈193.2m ; Y5≈158.5m
[DCF] Fair Price = 53.09 (EV 2.54b - Net Debt -103.8m = Equity 2.64b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow -14.22% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 0.09 | Revenue CAGR: 0.01% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=1.14 | Chg30d=+10.20% | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=1.00 | Chg30d=+1.22% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=3.84 | Chg30d=-1.61% | Revisions=-60% | GrowthEPS=-9.4% | GrowthRev=+2.7%
EPS next Year (2027-12-31): EPS=4.44 | Chg30d=-0.88% | Revisions=-33% | GrowthEPS=+15.8% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: -60%